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Background: The calcium-binding protein S100A12 correlates with measures of disease activity in patients with
rheumatoid arthritis (RA). The protein reflects neutrophil activation and the present objective was to explore in a pilot
study the associations between S100A12 and other inflammatory markers, clinical assessments as well as degree of
synovitis detected by a comprehensive ultrasonography (US) examination in RA patients during biologic treatment.
Methods: Twenty patients with RA were examined clinically and by use of US as well as laboratory markers S100A12,
calprotectin, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) before starting adalimumab, with
follow-up after 1, 3, 6 and 12 months. Ultrasonographic B-mode (BM) and power Doppler (PD) assessments of 78 joints,
36 tendons/tendon groups and 2 bursas were performed, and sum US scores calculated. Wilcoxon signed rank test
assessed treatment response and Spearman rank correlation test was used to calculate correlations.
Results: The concentrations of S100A12 decreased after 3 months (p < 0.01) and significant correlations were found
between S100A12 and the other laboratory markers during follow-up (0.50-0.62, p < 0.05). Of the clinical assessments,
S100A12 had highest correlations with the assessor’s global VAS (0.46-0.85, p < 0.05). Compared with CRP and ESR,
S100A12 showed higher correlations with the sum US scores (both BM and PD), with median (range) correlation
coefficients of 0.55 (0.35-0.78 (NS-p < 0.001)) for sum BM scores and 0.45 (0.27-0.75 (NS-p < 0.001)) for sum PD scores.
Conclusions: The S100A12 protein was significantly associated with other inflammatory markers, clinical assessments as
well as sum US scores, indicating that S100A12 is a potential marker of inflammation in RA patients.
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Rheumatoid arthritis (RA) is characterized by synovitis
that untreated may lead to joint damage and functional
disability. Even in clinical remission, a majority of patients
with RA had ongoing synovial inflammation as detected
by magnetic resonance imaging (MRI) or ultrasonography
(US) [1]. Use of these sensitive imaging modalities is ex-
pensive or time consuming, thus sensitive biomarkers* Correspondence: Hilde.Nordal@k2.uib.no
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siderable value for clinical decisions.
S100A12 is a calcium-binding protein, expressed pre-
dominantly in neutrophils, but also in monocytes [2,3].
It is released from activated neutrophils [4] and has pro-
inflammatory effects on endothelium and immune cells
that have been summarized in a review article [5].The
protein was up-regulated in synovial fluid in RA patients
compared with patients with osteoarthritis [6], and it dif-
ferentiated RA from other forms of inflammatory arthritis
when exploring synovial fluid [7]. S100A12 was increased
in serum of RA patients compared with healthy controls,
and was associated with the presence of rheumatoid factorLtd. This is an Open Access article distributed under the terms of the Creative
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Both in synovial fluid and in serum elevated levels of
S100A12 were found in erosive forms of RA compared
with non-erosive forms [9]. S100A12 was found in in-
flamed synovia of RA patients, but it was not expressed in
synovial tissue without inflammation [10]. Serum concen-
trations of S100A12 correlated with synovial fluid levels
and with measures of disease activity as erythrocyte sedi-
mentation rate (ESR) and Ritchie articular index [10].
S100A12 serum concentrations were also elevated in RA
patients before treatment with intra-articular corticoste-
roids or anti-tumour necrosis factor (anti-TNF), and de-
creased significantly in patients who responded to these
treatments [11]. S100A12 expression in synovia was also
reduced in these two groups after treatment [11]. Al-
though serum levels of S100A12 are increased in RA pa-
tients compared with controls [8,10], the upper normal
level in healthy persons has yet to be defined.
US is a sensitive imaging modality for detecting syno-
vitis in RA patients. The amount of synovitis is detected
by B-mode (BM). The degree of vascularization, reflect-
ing the inflammatory activity, is evaluated by use of
power Doppler (PD). A comprehensive US examination
of joints and tendons of RA patients may thus be able to
reflect the total amount of ongoing inflammation in
these structures.
The major leukocyte S100 protein, calprotectin (hetero-
complex of S100A8/A9), was investigated earlier in plasma
samples of this cohort and correlated with the US sum
scores [12]. The present pilot study explores the associa-
tions between serum levels of S100A12 and laboratory
and clinical assessments of disease activity, as well as US
sum scores from a comprehensive examination of joints
and tendons in a longitudinal follow-up of RA patients
starting biologic treatment.
Methods
Patients
Twenty patients (15 women and 5 men) with RA ac-
cording to the American Rheumatism Association 1987
revised criteria [13] with median (range) age 53 (21 to
78) years and disease duration 7.5 (1 to 26) years were
included as described elsewhere [14]. A total of 70%
were IgM RF positive and 80% ACPA positive. At inclu-
sion all patients used methotrexate as disease-modifying
anti-rheumatic drug (DMARD) (median (range) dose
17.5 (7.5-25) mg per week), 70% used prednisolone (me-
dian (range) dose 7.5 (3.75-15) mg per day) and two pa-
tients were on daily non-steroidal anti-inflammatory
drugs (NSAIDs). Median (range) DAS28 was 5.3 (3.4-
7.7) at baseline. The patients were included the day they
started treatment with adalimumab 40 mg every second
week as their first biologic agent. The study was ap-
proved by the Regional Committee for Medical andHealth Research Ethics, South-East (REK), and the pa-
tients gave written consent according to the Declaration
of Helsinki.
Laboratory analyses
Blood samples were drawn at inclusion and after 1, 3, 6
and 12 months of treatment with adalimumab. Conven-
tional inflammatory markers included ESR and CRP, ana-
lysed by use of in-house methodology, with upper normal
levels of 20 mm/h for ESR and 4 mg/L for CRP. Calpro-
tectin in plasma was examined by use of enzyme-linked
immunosorbent assay (ELISA) kits from CALPRO AS,
Norway. Sera from all five examinations were frozen at
−70°C. S100A12 concentrations in serum were determined
by ELISA as follows: 96-well high binding Costar 3590 mi-
cro plates from Costar Corporation, USA, were coated
with mouse monoclonal anti-S100A12 5 μg/mL in 0.1 M
sodium citrate pH 6, 150 μL per well, for 18 h to 4 weeks
at +5°C. Samples were diluted 1:5 using the sample dilu-
tion buffer. After washing the wells three times, 50 μL of
calibrators or samples were added in triplicate wells and
incubated at room temperature with shaking (500 rpm)
for 40 min. A second monoclonal was conjugated with al-
kaline phosphatase. After washing again, all wells were
added 50 μL of the ALP conjugate diluted 1:1000 and in-
cubated again for 40 min. After a final wash, all wells were
given 100 μL ALP substrate. Reading at 405 nm was per-
formed when the optical density (OD) of the higher stand-
ard (512 ng/mL) was between 2.0 and 3.0. For samples
with concentrations of 512 and 16 ng/mL the intra-assay
coefficients of variation were 6.5% and 10.6% and inter-
assay coefficients of variation were 2.3% and 10.9% re-
spectively. The lower limit of quantification of the ELISA
was 4 ng/mL. The reactivity and specificity of the anti-
bodies were previously tested by ELISA using micro wells
coated with S100A12 or calprotectin, which has consider-
able amino acid sequence homology to S100A12 [15].
Clinical assessments
Forty joints (proximal inter-phalangeals 1–5, metacarpo-
phalangeals 1–5, wrists, elbows, shoulders, knees, ankles
and metatarso-phalangeals 1–5) were assessed by one of
two experienced nurses for tenderness and swelling,
blinded for the results of the US examination. They also
scored the global disease activity on a visual analogue
scale (assessor’s global VAS). The disease activity score
DAS28 [16] was calculated.
Ultrasonography
US examinations were performed by one experienced
sonographer (HBH using a Siemens Antares Sonoline
machine; Siemens Medical Solutions, California, USA) at
the day of inclusion and after 1, 3, 6 and 12 months as
previously described [12,14]. A total of 78 joints and 36
Figure 1 Median levels (interquartile range) of the inflammatory
markers and ultrasonographic scores during 12 months follow-up.
a) Concentrations of S100A12. b) Concentrations of C-reactive protein
(CRP). c) Erythrocyte sedimentation rates (ESRs). d) B-mode (BM) sum
scores. e) Power Doppler (PD) sum scores. *Significantly decreased
levels from baseline, p<0.01.
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toid bursae were assessed for arthritis, tenosynovitis and
bursitis by grey scale or B-mode (BM) presence of syn-
ovial hypertrophy and fluid (scored together) and pres-
ence of power Doppler (PD) vascularization, both scored
on a 4–point scale (0 = no, 1 =minor, 2 =moderate, 3 =
major presence). The US examiner had no access to US
results from the previous examinations and was blinded
for the results from the clinical joint assessments and la-
boratory tests completed the same day.Statistics
Wilcoxon signed rank test was used to analyse the differ-
ences between the levels of S100A12, ESR, CRP and US
scores before starting adalimumab treatment and during
follow-up. Associations between laboratory markers, clin-
ical evaluations and US scores were analysed by use of
Spearman rank order correlations. IBM SPSS Statistics
version 20 was used for the statistical analyses and p <
0.05 was considered statistically significant. All tests for
significance were two-sided.Results
The patients had median (range) S100A12 levels of 49 (18
to 475) ng/mL at baseline, 34 (18 to 687) ng/mL after
1 month, 23 (16 to 173) ng/mL after 3 months, 33 (19 to
394) ng/mL after 6 months and 40 (12 to 620) ng/mL after
12 months. The level of S100A12, ESR and CRP changed
significantly from baseline to 3 months follow-up and ESR
already after 1 month, while the sum US scores decreased
significantly during follow-up (Figure 1).
There were significant correlations between S100A12
levels and sum US scores of all joints, tendons and bursae
for BM and PD at baseline, after one month and 6 months.
During the study, S100A12 showed higher correlation
coefficients with the US scores than the conventional
inflammatory parameters CRP and ESR (Table 1). The
correlations between S100A12 and the inflammatory
markers, as well as clinical assessments, are shown in
Table 2. Closest associations were found between
S100A12 and CRP/assessor’s global VAS. During follow-
up, different degree of correlation was found between the
leukocyte proteins S100A12 and calprotectin, from not
significant to moderately significant correlations.
Table 1 Spearman rank correlation coefficients between inflammatory markers and sum BM/PD scores
Baseline 1 month 3 months 6 months 12 months
S100A12 0.78***/0.75*** 0.68***/0.65*** 0.35/0.27 0.55*/0.45* 0.43/0.43
ESR 0.37/0.48* 0.36/0.35 0.45*/0.42 0.32/0.33 0.35/0.40
CRP 0.33/0.34 0.04/0.11 0.49*/0.35 0.59**/0.43 0.57**/0.55*
CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, BM = B-mode, PD = power Doppler, *p < 0.05, **p < 0.01, ***p < 0.001.
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The present one-year follow-up study of RA patients
starting treatment with adalimumab is the first to ana-
lyse the associations between serum levels of S100A12
and a comprehensive US joint examination, and signifi-
cant correlations were currently found.
All the inflammatory laboratory markers decreased
during the study. However, they tended to increase at
6 months onward (Figure 1), which could indicate re-
duced efficacy of the medication. It could be speculated
that it may be caused by development of antibodies
against adalimumab in some of the patients [17]. On the
other hand, this tendency was not seen for the US sum
scores [14]. A possible explanation could be that rise in
laboratory markers may be seen before changes in US
scores. It could also be speculated that, in parallel with
findings which suggest a possible dissociation between
disease activity and radiographic damage [18], there
could be a dissociation between the disease activity as
measured by inflammatory markers and US findings in
some patients treated with a biologic agent.
The S100A12 serum levels were lower in this study
than those reported for RA patients with active arthritis
[10,11]. The decrease following successful therapy was
also less pronounced than what has been reported previ-
ously [11]. This might be explained by the use of a dif-
ferent ELISA-test and thus the levels cannot be directly
compared. In addition, the levels of the other inflamma-
tory markers were rather low, even at baseline.
S100A12 correlated better and more consistently with
the comprehensive US sum BM and PD scores than the
conventional inflammatory parameters (Table 1). How-
ever, this might be partly explained by the low levels of the
conventional parameters, at least for CRP having a medianTable 2 Spearman rank correlation coefficients between S100
disease activity
Baseline 1 month
ESR 0.50* 0.29
CRP 0.61** 0.40
Calprotectin 0.56* 0.34
Assessor’s global VAS 0.85*** 0.58**
Swollen joints (of 40) 0.41 0.45*
DAS28 0.39 0.21
ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, VAS = visual analogue slevel of 4.5 mg/L at baseline. US is a sensitive modality for
detection of synovitis, and thus the present findings indi-
cate that the neutrophil protein S100A12 is a biomarker of
synovial inflammation in RA. Presently small and large
joints were equally weighted in the US scores, and thus
not exactly reflecting the total amount of synovitis. A lar-
ger study should include a weighting of joints taking into
account the size of the inflamed synovium. This might be
a more accurate way of assessing the associations between
US and the leukocyte proteins calprotectin and S100A12.
Although both S100A12 and calprotectin are released
by neutrophil activation, their correlations during follow-
up were presently found to be variable. S100A12 was not
superior to calprotectin as a biomarker for RA in this co-
hort, but the associations between these two S100 proteins
and clinical assessments and US scores should be explored
in further studies. Also S100A12’s ability to predict destruc-
tion should be assessed in larger cohorts of RA patients.
In a large cohort of patients with juvenile idiopathic
arthritis it was found that increased levels of S100A12 and
calprotectin, in addition to high-sensitivity C-reactive pro-
tein, indicated subclinical inflammation and thereby could
identify patients with increased risk of relapse when in
clinical remission [19]. Whether this is paralleled in RA,
remains to be shown. Many RA patients in clinical remis-
sion have remaining inflammatory activity of their joints
detected by US [1]. In our cohort a significantly higher
number of inflamed joints were found by US than by clin-
ical assessments at all the examinations [14]. Serum levels
of S100A12 may be of help to identify RA patients with
remaining inflammatory activity of joints.
The present study has several strengths. Primarily, this is
the first study exploring the associations between S100A12
serum levels and a comprehensive US examination. InA12 and inflammatory markers/clinical evaluations of
3 months 6 months 12 months
0.25 0.38 0.62**
0.50* 0.66** 0.59**
0.12 0.52* 0.57**
0.12 0.52* 0.46*
0.33 0.31 0.48*
0.23 0.34 0.51*
cale, DAS28 = disease activity score of 28 joints, *p < 0.05, **p < 0.01, ***p < 0.001.
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giving the possibility to study changes in S100A12 during
treatment with biologic medication. The weakness of this
pilot study is the limited number of patients included,
which reduces the strength of the present findings.
Conclusions
In this pilot study of 20 RA patients followed for 12 months
after initiation of adalimumab treatment, serum levels of
S100A12 were associated with clinical and laboratory as-
sessments as well as with a comprehensive ultrasono-
graphic examination. This indicates that S100A12 could be
a biomarker of synovitis in RA, and these promising find-
ings should be explored further in larger cohorts of RA pa-
tients to evaluate S100A12 as a marker of inflammation.
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